MI (myocardial infarction) redefinition set to impact global biomarker, ECG and imaging diagnostic policies
This article was originally published in Clinica
A major redefinition of myocardial infarction (MI) is soon to be unveiled, promising "significant implications" for clinical and research policy, including the use of ECG, biomarker and imaging diagnostics.
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.